news
Protein inhibitor could be new treatment for liver cancer
US scientists have found strong evidence for testing VCU-manufactured drugs in liver cancer.
List view / Grid view
Immuno-oncology
news
DNA barcoding reveals cancer cells’ ability to evade the immune system
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.
news
Cancer therapy shows potential to treat severe COVID-19 patients
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
news
Targeting of immune cells slows cancer growth in pre-clinical studies
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
news
Researcher develops nanoelectronics for personalised immunotherapies
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
news
Novel approach developed to deliver cancer immunotherapy drug
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
whitepaper
ebook: Current and emerging strategies for engineered cell therapies: cancer immunotherapy
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
whitepaper
Product hub: Uncover spatial biology secrets. Gain disease insights.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
news
Cancer immunotherapy drug discovery outsourcing size to increase globally
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
news
Novel method could determine which lymphoma patients will respond to CAR T-cell therapy
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
news
Blocking trogocytosis improves ability of CAR T-cell therapy to treat cancer in mice
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
news
New immunotherapy method to find antigens that trigger specific T cells
The approach mimics the physical forces exerted by T cells as they crawl over host cells, could help scientists develop more effective cancer immunotherapies.
